This report was first published by Endpoints News. To see the original version, click here
The FDA threw its support behind a dozen peptides, announcing plans to reclassify them, likely presenting a huge money-making opportunity for what’s been a largely opaque market to-date.
The agency said in a document posted Wednesday that it plans to remove the products from category 2, defined as a bulk drug substance that raises significant safety concerns. The decision was announced by HHS Secretary Robert F. Kennedy Jr. in a post on X, who wrote that “this action begins to restore regulated access and will immediately begin shifting demand away from the black market.”
您已阅读17%（667字），剩余83%（3235字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。